10x Genomics (NASDAQ:TXG) vs. Bullfrog AI (NASDAQ:BFRG) Head-To-Head Contrast

10x Genomics (NASDAQ:TXG) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares 10x Genomics and Bullfrog AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
10x Genomics	-25.14%	-23.22%	-18.02%
Bullfrog AI	N/A	-163.23%	-139.94%

Volatility and Risk

10x Genomics has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500.

Institutional & Insider Ownership

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by insiders. Comparatively, 33.9% of Bullfrog AI shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares 10x Genomics and Bullfrog AI”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$624.66 million	2.46	-$182.63 million	($1.30)	-9.59
Bullfrog AI	$60,000.00	237.07	-$6.99 million	($0.81)	-1.86

Bullfrog AI has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for 10x Genomics and Bullfrog AI, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1	5	7	0	2.46
Bullfrog AI	0	0	0	0	0.00

10x Genomics presently has a consensus target price of $14.13, suggesting a potential upside of 13.27%. Given 10x Genomics’ stronger consensus rating and higher possible upside, research analysts plainly believe 10x Genomics is more favorable than Bullfrog AI.

Summary

10x Genomics beats Bullfrog AI on 8 of the 14 factors compared between the two stocks.

About 10x Genomics

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.